Trial · NCT00931606
Results by group250
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 250
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.1 mg/kg | Overall | 0 | 95% Confidence Interval 0 to 52.2 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.3 mg/kg | Overall | 33.3 | 95% Confidence Interval 7.5 to 70.1 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.5 mg/kg | Overall | 50.0 | 95% Confidence Interval 6.8 to 93.2 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Placebo | Overall | 20.0 | 95% Confidence Interval 0.5 to 71.6 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | All Sotatercept-treated Participants | Overall | 27.8 | 95% Confidence Interval 9.7 to 53.5 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.1 mg/kg | Received weekly chemotherapy and showed a response | 0 | 95% Confidence Interval 0 to 84.2 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.3 mg/kg | Received weekly chemotherapy and showed a response | 0 | 95% Confidence Interval 0 to 84.2 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.5 mg/kg | Received weekly chemotherapy and showed a response | 25.0 | 95% Confidence Interval 2.5 to 100.0 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Placebo | Received weekly chemotherapy and showed a response | 20 | 95% Confidence Interval 2.5 to 100.0 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | All Sotatercept-treated Participants | Received weekly chemotherapy and showed a response | 5.6 | 95% Confidence Interval 0.5 to 71.6 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.1 mg/kg | Received less frequent chemotherapy and showed a response | 0 | 95% Confidence Interval 0 to 70.8 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.3 mg/kg | Received less frequent chemotherapy and showed a response | 33.3 | 95% Confidence Interval 9.9 to 81.6 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Sotatercept 0.5 mg/kg | Received less frequent chemotherapy and showed a response | 25.0 | 95% Confidence Interval 0.8 to 90.6 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | Placebo | Received less frequent chemotherapy and showed a response | 0 | 95% Confidence Interval 0 to 60.2 | Percentage of Participants |
| Percentage of Participants Who Achieved a Hematopoietic Response | All Sotatercept-treated Participants | Received less frequent chemotherapy and showed a response | 22.2 | 95% Confidence Interval 9.1 to 61.4 | Percentage of Participants |
| Number of Participants Who Experienced an Adverse Event (AE) | Sotatercept 0.1 mg/kg | 6 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Sotatercept 0.3 mg/kg | 7 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Sotatercept 0.5 mg/kg | 7 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Placebo | 5 | Participants | ||
| Number of Participants Who Discontinued Study Intervention Due to an Adverse Event | Sotatercept 0.1 mg/kg | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00931606/results